Why did MRNA's Q2 2024 EPS exceed forecasts significantly?

Moderna's Q2 2024 EPS exceeded forecasts significantly due to a combination of factors:

1. **Revenue from COVID-19 Vaccine Sales**: Moderna's revenue was boosted by sales of its COVID-19 vaccine, which continued to generate substantial income despite the overall decline in vaccine demand.
2. **Cost Management**: The company implemented effective cost management strategies, leading to a 27% reduction in costs compared to the previous year. This included measures such as resizing their manufacturing footprint, renegotiating pricing, and enhancing operational efficiencies.

In conclusion, Moderna's Q2 2024 EPS exceeded forecasts significantly due to a combination of revenue from COVID-19 vaccine sales and effective cost management.